3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
2
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
2
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
59
Leukemia
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Gastrointestinal Stromal Tumors
12
Leukemia, Myeloid, Chronic-Phase
11
Neoplasms
5
Blast Crisis
4
Recurrence
3
Bronchiolitis Obliterans Syndrome
3
Synovitis, Pigmented Villonodular
2
Philadelphia Chromosome
2
Neoplasm Metastasis
2
Melanoma
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia, Myeloid
2
Hematologic Diseases
2
Bone Marrow Diseases
2
Sarcoma
1
Piebaldism
1
Peritoneal Neoplasms
1
Ovarian Neoplasms
1
Neurofibromatoses
1
Neurofibroma, Plexiform
1
Neurofibroma
1
Neoplastic Processes
1
Myeloproliferative Disorders
1
Mucosal Lentiginous Melanoma
1
Mastocytosis, Systemic
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Non-Hodgkin
1
Interventions
ruxolitinib
4
Imatinib Mesylate
3
ponatinib
2
nilotinib
2
Azacitidine
2
spartalizumab
1
sonidegib
1
simtuzumab
1
sabatolimab
1
bosutinib
1
Zoledronic Acid
1
SCIO-469
1
Lenalidomide
1
Denosumab
1
Decitabine
1
Clofarabine
1
CPI-0610
1
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Bone Marrow Diseases
×
nilotinib
×
Clear all
NCT01844765
2021-04-22
DIALOG
Novartis
Phase 2
Completed
59 enrolled
33 charts
1 FDA
NCT00471497
2020-11-18
ENESTnd
Novartis
Phase 3
Completed
846 enrolled
33 charts